MA48464A - N-ACETYLATED AND NON-ACETYLATED DIPEPTIDES CONTAINING ARGININE FOR REDUCING THE VISCOSITY OF VISCOUS COMPOSITIONS OF THERAPEUTIC POLYPEPTIDES - Google Patents

N-ACETYLATED AND NON-ACETYLATED DIPEPTIDES CONTAINING ARGININE FOR REDUCING THE VISCOSITY OF VISCOUS COMPOSITIONS OF THERAPEUTIC POLYPEPTIDES

Info

Publication number
MA48464A
MA48464A MA048464A MA48464A MA48464A MA 48464 A MA48464 A MA 48464A MA 048464 A MA048464 A MA 048464A MA 48464 A MA48464 A MA 48464A MA 48464 A MA48464 A MA 48464A
Authority
MA
Morocco
Prior art keywords
acetylated
viscosity
reducing
therapeutic polypeptides
viscous compositions
Prior art date
Application number
MA048464A
Other languages
French (fr)
Inventor
Neeraj Jagdish Agrawal
Pavan Ghattyvenkatakrishna
Sekhar Kanapuram
Christopher James Sloey
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of MA48464A publication Critical patent/MA48464A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183Amino acids, e.g. glycine, EDTA or aspartame
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401Proline; Derivatives thereof, e.g. captopril
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/4172Imidazole-alkanecarboxylic acids, e.g. histidine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05Dipeptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591Stabilisation, fragmentation
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06Dipeptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
MA048464A 2017-04-28 2018-04-27 N-ACETYLATED AND NON-ACETYLATED DIPEPTIDES CONTAINING ARGININE FOR REDUCING THE VISCOSITY OF VISCOUS COMPOSITIONS OF THERAPEUTIC POLYPEPTIDES MA48464A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201762492020P 2017-04-28 2017-04-28

Publications (1)

Publication Number Publication Date
MA48464A true MA48464A (en) 2020-03-04

Family

ID=62165708

Family Applications (1)

Application Number Title Priority Date Filing Date
MA048464A MA48464A (en) 2017-04-28 2018-04-27 N-ACETYLATED AND NON-ACETYLATED DIPEPTIDES CONTAINING ARGININE FOR REDUCING THE VISCOSITY OF VISCOUS COMPOSITIONS OF THERAPEUTIC POLYPEPTIDES

Country Status (7)

Country Link
US (1) US12103979B2 (en)
EP (1) EP3615069B1 (en)
AU (1) AU2018258676B2 (en)
CA (1) CA3279830A1 (en)
ES (1) ES3036143T3 (en)
MA (1) MA48464A (en)
WO (1) WO2018201064A1 (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI856084B (en) * 2019-04-01 2024-09-21 美商建南德克公司 Compositions and methods for stabilizing protein-containing formulations
CN113660927A (en) * 2019-04-23 2021-11-16 安进公司 Viscosity reduction of high concentration protein formulations using low molecular weight polyvinylpyrrolidone (PVP)
US20230242655A1 (en) 2019-12-03 2023-08-03 Evotec International Gmbh Interferon-associated antigen binding proteins and uses thereof
WO2021243298A1 (en) * 2020-05-29 2021-12-02 Chinook Therapeutics, Inc. Methods of treating iga nephropathy with an april binding antibody
EP4238578A4 (en) * 2020-10-30 2024-09-11 Eisai R&D Management Co., Ltd. PHARMACEUTICAL COMPOSITION
US20220193238A1 (en) * 2020-12-17 2022-06-23 Astrazeneca Ab Anti-il5r antibody formulations
EP4302778A4 (en) * 2021-03-03 2025-03-12 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Pharmaceutical composition containing anti-tslp antibody
US20240343795A1 (en) * 2021-08-12 2024-10-17 Amgen Inc. Antibody formulations
US12110324B2 (en) 2022-07-22 2024-10-08 Flagship Pioneering Innovations Vi, Llc Antigen binding molecules targeting thymic stromal lymphopoietin (TSLP)

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69120146T2 (en) 1990-01-12 1996-12-12 Cell Genesys Inc GENERATION OF XENOGENIC ANTIBODIES
US6767892B1 (en) 1997-11-07 2004-07-27 Chrion Corporation Compositions providing for increased IGF-I solubility
RS51829B (en) 2001-08-23 2012-02-29 Genmab A/S. HUMAN ANTIBODIES SPECIFIC TO INTERLEUKIN 15 (IL-15)
US7906625B2 (en) 2005-01-24 2011-03-15 Amgen Inc. Humanized anti-amyloid antibody
US7592429B2 (en) 2005-05-03 2009-09-22 Ucb Sa Sclerostin-binding antibody
US8003108B2 (en) 2005-05-03 2011-08-23 Amgen Inc. Sclerostin epitopes
WO2008154014A2 (en) 2007-06-11 2008-12-18 Amgen Inc. A method for culturing mammalian cells to improve recombinant protein production
CN102027012A (en) 2007-06-20 2011-04-20 Irm责任有限公司 Methods and compositions for treating allergic diseases
US7982016B2 (en) 2007-09-10 2011-07-19 Amgen Inc. Antigen binding proteins capable of binding thymic stromal lymphopoietin
TWI516501B (en) 2008-09-12 2016-01-11 禮納特神經系統科學公司 Pcsk9 antagonists
BR112012027828A2 (en) * 2010-05-03 2016-08-09 Genentech Inc matter composition, article of manufacture and method of reducing the viscosity of a protein containing formulation and preparing an aqueous protein containing formulation
WO2015196091A1 (en) * 2014-06-20 2015-12-23 Reform Biologics, Llc Viscosity-reducing excipient compounds for protein formulations
AU2015289874A1 (en) 2014-07-14 2017-02-02 Amgen Inc. Crystalline antibody formulations
WO2016065181A1 (en) * 2014-10-23 2016-04-28 Amgen Inc. Reducing viscosity of pharmaceutical formulations

Also Published As

Publication number Publication date
WO2018201064A1 (en) 2018-11-01
ES3036143T3 (en) 2025-09-15
AU2018258676A1 (en) 2019-10-31
EP3615069B1 (en) 2025-05-28
CA3279830A1 (en) 2026-03-02
AU2018258676B2 (en) 2024-09-19
US12103979B2 (en) 2024-10-01
US20200048367A1 (en) 2020-02-13
CA3059369A1 (en) 2018-11-01
EP3615069A1 (en) 2020-03-04

Similar Documents

Publication Publication Date Title
MA48464A (en) N-ACETYLATED AND NON-ACETYLATED DIPEPTIDES CONTAINING ARGININE FOR REDUCING THE VISCOSITY OF VISCOUS COMPOSITIONS OF THERAPEUTIC POLYPEPTIDES
MA51796A (en) METHODS AND COMPOSITIONS FOR THE ADMINISTRATION OF THERAPEUTIC PROTEINS
EP3880717A4 (en) COMPOSITIONS AND METHODS OF DELIVERING CRISPR/CAS-EFFECTING POLYPEPTIDES
EP3880688A4 (en) PREPARATIONS AND COMPOSITIONS OF OLIGOSACCHARIDES
PL3717471T3 (en) NEW COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM FOR THE TREATMENT OF DISEASES
MA47688A (en) USEFUL COMPOSITIONS IN THE TREATMENT OF SPINAL AMYOTROPHY
EP3427601A4 (en) COMPOSITION OF SYRUP CONTAINING ALLULOSE AND FOOD CONTAINING THE SAME
MA45688A (en) COMPOSITIONS AND METHODS FOR THE POTENTIALIZATION OF ANTIMICROBIAL AGENTS
EP3412660A4 (en) SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL COMPOSITION CONTAINING SAME
EP3777866A4 (en) PHARMACEUTICAL COMPOSITION AND APPLICATION OF THE LATTER
EP3413887A4 (en) INTERMEDIATES USED IN THE SYNTHESIS OF ÉRIBULINE AND ASSOCIATED METHODS OF SYNTHESIS
SG11202009574RA (en) Combinations of osteopontin and 2'-fucosyllactose for use as medicaments
PL3810128T3 (en) COMPOSITIONS FOR THE TREATMENT AND/OR PREVENTION OF PROTEIN AGGREGATION DISEASES
IT201700085412A1 (en) Composition for use in the prevention and treatment of cardiovascular diseases
EP3785698A4 (en) PHARMACEUTICAL COMPOSITION OF EDARAVONE
EP3679863A4 (en) SEALANT SYRINGE SET
EP3648773A4 (en) COMPOUNDS AND METHODS FOR THE TRANSMEMBRANARY ADMINISTRATION OF MOLECULES
EP3817750A4 (en) COMPOSITIONS OF CANNABIDIOL ASSOCIATIONS
MA49524A (en) NK-1 ANTAGONIST COMPOSITIONS AND METHODS FOR USE IN THE TREATMENT OF DEPRESSION
EP3484434A4 (en) OIL-IN-WATER FOAMS CONTAINING BETULIN AND COMPOSITIONS THEREOF
EP3675858A4 (en) COMPOUNDS AND COMPOSITIONS FOR INHIBITION OF IRE1
EP3542821A4 (en) MOLECULE INDUCING THE DEGRADATION OF p53 AND PHARMACEUTICAL COMPOSITION
EP3638277A4 (en) COMPOSITIONS AND METHODS FOR INHIBITION OF BETA-SECRETASE
EP3255113C0 (en) ADHESIVE AND/OR SEALANT COMPOUND
EP3756700A4 (en) COMPOSITION OF LIQUID EMBOLIC AGENT